A respected provider of biopharmaceutical products in China.

, a respected provider of biopharmaceutical products in China, announced today that Sinovac has received its second purchase purchase because of its H1N1 vaccine, PANFLU.1, from the Ministry of Industry and IT of the People’s Republic of China for the nationwide stockpiling plan. Under this purchase order, Sinovac is required to produce yet another 3 million dosages of PANFLU.1 , Sinovac’s H1N1 vaccine for the central authorities. The 3 million dosage purchase purchase announced today is in addition to the initial order for 3. 3 million doses received from the Ministry of Market and IT of China on September 4, 2009. Sinovac is likely to total the delivery of 4.5 million doses of PANFLU.of October 1 to the Chinese central government by the finish. Related StoriesNew study may offer approaches for developing toxoplasma-inactivated vaccineResearch provides network marketing leads for new strategies to develop HIV vaccineResearchers reveal why malaria vaccine provides only moderate protection among vaccinated childrenTo time, a lot more than 100,000 citizens in Beijing have already been inoculated by PANFLU.1, Sinovac’s H1N1 vaccine and no severe adverse occasions have been reported, demonstrating the nice basic safety profile of Sinovac’s H1N1 vaccine.The new software release includes a significantly updated user interface and patient database, and supports market integration standards into electronic medical record environments. The new software can help physicians streamline the practice workflow and allow them to access a patient’s test results electronically through their EMR systems. The new software supports main industry reporting standards including HL7 and DICOM, optimizing connection to leading electronic medical records systems on the market. The software will be available to all existing and clients and will begin shipping in May. Related StoriesRaising lupus awareness: an interview with Professor Ramsey-Goldman, MDMarriage status linked to survival outcomes pursuing cardiac surgeryMultimodality at the Center for Advanced Biomedical Imaging: an interview with Professor Mark Lythgoe, UCLAli Haghighi-Mood, CEO of Cambridge Heart, said, ‘This new software program will enable our customers, particularly multi-physician procedures and hospitals, to realize a rise in the usability of our items, and supports their goals of a transition into EMR conditions by providing compatibility with industry requirements.